OSE-279 

OSE-279 is a high-affinity humanized monoclonal bivalent antibody targeting PD-1, the recommended isotype control is HY-P99003. OSE-279 blocks PD-1 ligand binding, inhibits PDL1-induced SHP1 phosphorylation, restores T cell activation, and promotes reactivation of primary T cell effector functions. OSE-279 binds hFcRn receptor, predicts long half-life, induces CD4 and CD8 T cell proliferation, and promotes interleukin 2 and interferon gamma secretion. OSE-279 can be used for the research of advanced malignancies, colon cancer, hepatocarcinoma, mesothelioma^[1][2].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

OSE-279 blocks PD-1 binding to PD-L1 with an IC₅₀ of 308 ng/mL and to PD-L2 with an IC₅₀ of 911 ng/mL in cell-free binding assays^[2].
OSE-279 inhibits PD-L1-induced SHP1 phosphorylation in a cell-based assay with an IC₅₀ of 14.19 ng/mL^[1].
OSE-279 reactivates primary T cell effector functions in an MLR assay, inducing interleukin 2 and interferon γ secretion^[1].
OSE-279 shows good affinity to the human FcRn receptor, predicting a long half-life in humans^[1].
OSE-279 restores T cell activation via inhibition of pSHP-1 signalling in cell-based assayS^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

OSE-279 exerts potent antitumor activity with long-term responses and improved survival in syngeneic colon cancer, hepatocarcinoma, and mesothelioma models in immunocompetent PD1 Knock-in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

5133  [NCBI]

Q15116

PDCD1/PD-1/CD279

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Philippe Cassier, et al. Abstract C063: OSE279, a PD-1 blockingmonoclonal antibody, as future backbone of a bifunctional checkpoint inhibitor platform:Preclinical characterization and early clinical results of a First-In-Human (FIH) study in subjectswith advanced malignancies [abstract]. In: Proceedings of the AACR-NCI-EORTC VirtualInternational Conference on Molecular Targets and Cancer Therapeutics. Mol Cancer Ther (2023) 22 (12 Supplement): C063.

  [2]. Robert M, et al. A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours. Eur J Cancer. 2026;240:116729.